• Research shows one in three cannabis users drink less alcohol when compared to before legalization, 84% feel cannabis is safer, nearly half (47%) prefer cannabis over alcohol
• BevCanna specializes in the production of in-house and white-label cannabis-infused beverages using Canadian premium alkaline spring water
• BevCanna’s HACCP-certified, 40,000 square foot manufacturing facility operating by GMP standards, current capacity at 210 million bottles per annum
• Extensive retail network spans 3,000+ points of distribution throughout North America

Cannabis-infused beverages are increasing in popularity as the drink of choice for consumers in social settings — a trend that some analysts believe threatens the alcoholic beverage industry (https://ibn.fm/wS24C). BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), a diversified health & wellness beverage and natural products company, is positioned to take a sizeable share of the growing market through its focus on quality ingredients, iconic branding, and a retail strategy that leverages over 3,000 points of distribution across North America. Cannabis-infused beverages have rapidly grown in popularity, likely due to their water-soluble nature that allows cannabinoids to absorb quickly into the bloodstream and produce euphoric effects. According to a research report by ICR Strategic Communications and Spectacle, the general use of cannabis and cannabis-infused products has resulted in decreased alcohol use among surveyed participants. According to the research, one in three users report drinking less alcohol than before cannabis legalization, 84% of respondents feel that cannabis is safer than alcohol, and that nearly half (47%) prefer the effects of cannabis over alcohol (https://ibn.fm/ZxIbp). “With market reports and surveys showing that more consumers are seeking alternatives to alcoholic beverages for health and wellness reasons, the rapidly evolving cannabis beverage category is a real game changer,” said Ben Larson, founding board member of the Cannabis Beverage Association (https://ibn.fm/a2HX2). “These drinks can be stimulating, and thanks to cutting-edge technology, taste great and have a quick onset time with precise dosage so one can predict and control the desired effect, similar to knowing how you’ll feel after one glass of wine or beer.” Larson is also the CEO of Vertosa, a preferred cannabis emulsion partner of BevCanna. Vertosa will be the emulsion in BevCanna’s Keef beverages, which it plans to launch across Canada (https://ibn.fm/xTsVY). BevCanna specializes in the production of both in-house and white-label cannabis-infused beverages using premium alkaline spring water bottled at the company’s facility in British Columbia, Canada. With a current capacity of 210 million bottles per annum, the company’s 40,000 square foot beverage and supplement manufacturing facility is HACCP-certified and built to GMP standards with pre-approval by the Agricultural Land Commission to expand the facility to 170,000 square feet. BevCanna’s vision is to be a global leader in health and wellness. The company’s extensive retail network spans 3,000+ points of distribution throughout North America and includes its market-leading TRACE alkaline and mineralized water brand, its Pure Therapy natural health and wellness e-commerce platform, its fully licensed Canadian cannabis manufacturing and distribution network, and a partnership with Keef Brands – the #1 cannabis beverage company in the United States. For more information on BevCanna, visit the company’s website at www.BevCanna.com. NOTE TO INVESTORS: The latest news and updates relating to BVNNF are available in the company’s newsroom at http://ibn.fm/BVNNF

• Red White & Bloom released its Q4 2020 and FY 2020 results and later reported its Q1 2021 results
• In its Q4 2020 results, the company posted a 158% quarter-over-quarter increase in revenue from $CA6.1 million in Q3 2020 to $15.7 million
• Its FY revenue grew from nil in 2019 to CA$23.3 million in 2020, while its gross profit was CA$13.35 million in 2020 from nil in 2019
• RWB reported $32.7 million in Q1 2021 adjusted sales, an increase of 14.5% over Q4 2020

In a statement contained in the company’s December 2020 investor deck presentation, Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) CEO Brad Rogers observed that multiple deals, “judiciously purchased and diligently structured,” were all coming together to create “the most exciting times in the history of the company.” He further noted that the company was looking to build on its key assets focusing on growing the bottom line for its shareholders (https://ibn.fm/yqIO2). Red White & Bloom recently made two announcements that show its progress thus far and perhaps tell of the dawn of the exciting times. On July 22, the company announced its Q4 2020 and full-year results (https://ibn.fm/ikseA). RWB reported a 158% quarter-over-quarter increase in revenue from CA$6.1 million in Q3 2020 to CA$15.7 million in Q4 2020. The company attributes this increase to the impact of the acquisition the Platinum Premium Cannabis Products (“PV”) on its balance sheet, given that Q4 2020 was the first full quarter post-closing. RWB’s revenue for the year ended December 31, 2020, grew to CA$23.3 million from nil in 2019, while its gross profit for the FY 2020 was CA$13.35 million, or 57% of the FY revenue, compared to nil in 2019. Red White & Bloom closed FY 2020 having made significant strides as it seeks to be the superior and most recognizable cannabis company in the United States. It completed two transformative acquisitions: PV, which is licensed in California and has products being sold in Oklahoma and Michigan, and Mid-American Growers (“MAG”), a company that owns a 3.6-million-square-foot, state-of-the-art technology and science facility that will enable RWB to attain premium value for the products it wishes to cultivate. The company has also raised more than US$110 million since January 1, 2020, which it expects will support its expansion and operations. Additionally, as of July 2, 2021, it had about CA$41 million cash on hand. The company reports adjusted sales for the 1st quarter of $32.7 million, a sequential increase of 14.5% from the prior quarter’s adjusted sales of $28.6 million in Q4 2020. The increase was reduced by the strengthening Canadian dollar and would have been about $1 million higher using a constant dollar comparison (https://ibn.fm/KVHvC). “This was another great quarter for the company as we continued to see strong traction for our brands,” said Brad. “We are building on that momentum and working towards finalizing our revised asset purchase of our Michigan investee to bring their revenue, as well as adjusted sales into IFRS revenue format before the end of this current quarter.” Once this is complete and the expansion of its Florida operations starts bearing fruits, the company expects to finally report in its quarterly results the strength of its accomplishments so far. As such, more is still to come for Vancouver-based Red White & Bloom as it positions itself to be one of the top three multi-state operators in the United States in cannabis and hemp-derived product lines. For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

• Flora Growth Corp. is a Colombian cannabis cultivator that is building a global cannabis CPG portfolio of premium brands and products
• Flora Growth recently announced an LOI designed to grant it an in-road to Australia’s over-the-counter medical cannabis and CBD commercial markets
• The company also signed an LOI to distribute popular Canadian pain topical brand KaLaya throughout Latin American countries, with exports planned to the United States, and to infuse its established line of products with CBD
• Market analysts predict Australia’s medial cannabis market will explode from about $150 million this year to more than a billion dollars by 2025

The Colombia-based operations of cannabis cultivator, global brand builder and product distributor Flora Growth (NASDAQ: FLGC) are receiving increased attention from market watchers, particularly in the wake of the company’s announcement that it executed a letter of intent (“LOI”) with Australia’s Evergreen Pharmacare Pty Ltd. to supply medical-grade dried flower and derivative cannabis products to Australians through Evergreen’s pharmacy distribution network. A July 27 statement issued by Flora Growth indicated Evergreen helps patients and healthcare practitioners, primarily physicians and pharmacists, obtain medical cannabis products and provides them with additional cannabis-related education about its use, authorization and regulation. Flora Growth will begin shipping its medical-grade cannabis products as soon as it harvests its first commercial crop and secures the necessary export licenses (https://ibn.fm/pkkht). Market analysts at FreshLeaf Analytics (https://ibn.fm/5v5ce) and Prohibition Partners (https://ibn.fm/gGdZy) predict the medical cannabis segment will range in value from about US$150 million this year to up to US$1.5 billion by 2025, and the LOI between Flora Growth and Evergreen positions the Colombian grower (with headquarters in Miami, Florida) at the leading edge of a burgeoning market. “This agreement also provides significant potential upside by allowing us to work with Australian regulators directly and bring our premium brands and established product formulations to the over-the-counter CBD market,” Chief Revenue Officer Jason Warnock stated in the company’s news release, adding that Australian regulators’ recent decision to down-schedule cannabidiol (“CBD”) to a level where it can be sold as an over-the-counter product opens the door to Flora’s strategy for “providing proven cannabinoid wellness and beauty products to consumers around the world.” Flora Growth also recently announced that it has signed an LOI to form a joint venture with Canadian-based Avaria Inc., which manufactures pain cream under its flagship brand KaLaya. KaLaya is distributed nationwide across Canada and anticipates distribution across Latin American countries under the JV, with exports to the United States as Flora Growth manages registration, sales and distribution needs. The upside here is not only bringing these well-received products to international markets, but to also infuse these products with cannabinoids, particularly CBD, in order to generate incremental revenue. Avaria does not currently hold a license in Canada to produce cannabis derived versions of its products at a commercial scale, so the partnership would see Flora Growth’s lab division providing it with a necessary boost to expand its market reach as it supplies the cannabis derivative products and low-cost manufacturing locally in Colombia. In Canada, KaLaya has been recognized as the most popular topical analgesic brand distributed through Canadian retailer Purity Life and by The Shopping Channel in 2020, weighing in as Canada’s fastest growing topical decongestants and analgesics brand, according to Nielsen Market Track. “Given CBD’s association with wellness, KaLaya’s established formulation, and Flora Growth’s low-cost high-quality cannabis, this is a natural partnership we are excited to bring globally,” Flora Growth President and CEO Luis Merchan stated in the news release. For more information, visit the company’s website at www.FloraGrowth.ca. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• American Academy of Neurology warns of critical neurologist shortfall amid increased incidence of brain disorders
• Brain Scientific addresses issue with portable, cost-effective brain diagnostic solutions that record EEGs in nearly any setting
• Product development includes creation of AI and ML algorithms to detect seizures, dementia and other brain-related conditions
• NeuroCap and NeuroEEG device patents approved in U.S., Europe and China

With a goal of addressing the current acute neurologist shortfall in the United States (https://ibn.fm/DrxvC), Brain Scientific (OTCQB: BRSF), a commercial-stage health care company, has developed cost-effective and portable proprietary medical devices that are positioned to disrupt the electroencephalogram (“EEG”) market. According to a report from the American Academy of Neurology 2019 Transforming Leaders Program, nearly every U.S. state is experiencing a neurologist shortfall amid an increase in neurological disorders (https://ibn.fm/DrxvC). Experts warn that access to high-level care and diagnosis is immediately required to reduce mental disability, improve patient outcomes and increase the wellbeing of the current pool of neurologists facing quality of life issues. As part of the effort to address the shortfall, Brain Scientific aims to support the industry with the introduction of cost-effective, disposable brain diagnostic solutions that include the NeuroCap(TM) and NeuroEEG(TM). These portable devices are part of the company’s expanded vision for neurology telemedicine, allowing practitioners to collect diagnostic information quickly, upload it to cloud-based infrastructure, and leverage artificial intelligence (“AI”) and machine learning (“ML”) algorithms to detect seizures, dementia and other brain-related conditions. Brain Scientific’s go-to-market strategy emphasizes relationships with leading hospitals, in addition to prioritizing the creation of partnerships with industry leaders in EEG manufacturing and distribution. With an aim to further increase market penetration, the company endeavors to integrate its EEG solution with existing telemedicine platforms to serve the direct neurology market in addition to bundling its diagnostic solutions with products in related sectors to service complimentary markets. The first phase of the company’s three-stage development process was completed in 2019 with the creation of the NeuroCap and NeuroEEG devices. Currently in its second development phase, Brain Scientific is now focused on the creation of secure cloud-based infrastructure to transmit data between neurologists and patients. The final phase, scheduled for late 2021 and 2022, will focus on the development of AI and ML functionality to provide predictive analytics that increases the diagnostic capabilities offered by its devices. Brain Scientific’s NeuroCap and NeuroEEG devices can be used to record EEGs in settings of all types such as neurology clinics, remote clinical research labs, emergency departments, urgent care clinics, ICUs, nursing homes and assisted living facilities. With patents already approved in the United States, Europe and China, the company is positioned to dominate the market for portable brain imaging devices to address the current neurologist shortfall, improve patient outcomes and expand its vision for telemedicine in the neurology industry. For more information on Brain Scientific Inc., visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Mobius Interactive Ltd. is strategically targeting global iGaming hotspots with three unique brands
• Club Double is targeting the emerging iGaming market in India
• Mobius.bet is expanding rapidly in the Brazilian market, as a top television sponsor for both the 2021/22 World Cup Qualifiers and for Italian Serie A football in August 2021
• Aragon Casino will target the regulated Canadian market

Mobius Interactive, a Vancouver-based online gaming company, has three distinct brands: Mobius.bet , Club Double and Aragon Casino. Paired with unique design and style, each brand targets specific geographical regions and demographics—offering a diverse and innovative iGaming experience to a wide range of players the world over. India is the fastest growing iGaming market in the world with an industry valued at $930m. Due to low-cost data, rising disposable incomes and the rollout of 5G, India was #1 in mobile downloads worldwide last year, downloading an astonishing 7.3 billion games. Club Double was created to tap into this emerging market, with the aura of old Hollywood and vintage Las Vegas in mind. This nostalgic brand aligns perfectly with the Bollywood genre, translating into early success for Mobius Interactive. Cricket is the most watched sport in India. Club Double is moving forward into the lucrative Indian market, with sports betting and a monthly calendar of events featuring daily cricket matches, not only inside of India, but all cricket games played around the world. Another national pastime is card games. For card players, Club Double provides the most popular live casino and casino games in the country. Aragon Casino brands itself along the lines of medieval and modern fantasy, echoing The Walking Dead and Game of Thrones. Aragon Casino, operating currently in Austria, Finland, the Balkans, Africa, and New Zealand, will move away from these regions and target the newly regulated Canadian market, beginning with Ontario. Mobius.bet is the flagship brand of Mobius Interactive, connecting players and a worldwide Esports community through loyalty programs and targeted gamification. Mobius.bet geographically focuses on Austria, Switzerland, Brazil, Latin America, and New Zealand. Mobius.bet will be launching into the Brazilian market on national TV with Serie A football starting 21 August 2021, followed by the 2021/22 FIFA World Cup Qualifiers. The soccer world is electric in Brazil: The Brazilian Olympic Team has just won back-to-back gold medals in soccer: a feat last accomplished by Argentina in 1908. The top World Cup qualifying match between the two greatest soccer rivals in the world, Brazil vs. Argentina, is expected to draw 40 million viewers on Globo TV Brazil.  Mobius Interactive is open for investment opportunities. For further information please contact: Gary Eldridge – President 1 (604) 783-1685   gary@mobiusinteractive.ltd  Seamus Byrne – VP Corporate Development 1 (902) 441-5757   seamus@mobiusinteractive.ltd For more information, visit the company’s website at www.MobiusInteractive.Ltd.  NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius

• Naturo Group signs contract with BC Wildfire Services Division; will provide special bottled water to over 1,100 firefighters across British Columbia.
• TRACE-branded natural 7.7ph alkaline spring water is sourced directly the source in British Columbia, the very land the firefighters protect.
• BevCanna’s TRACE product line features unique, ancient minerals that offer a broad range of wellness properties including cognitive performance, immune function and gut health.

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) has announced that its wholly owned subsidiary Naturo Group has been selected to manufacture and supply a special, limited-edition run of its TRACE-branded, alkaline spring water to the Wildfire Services Division of the British Columbia Ministry of Forests, Lands, Natural Resource Operations and Rural Development (https://ibn.fm/Mvduv). The division is globally renowned for its wildfire management and employs 1,100 Type 1 firefighters who respond to nearly 1,600 wildfires annually throughout British Columbia. “We’re pleased that we’ve been awarded the contract with BC Wildfire Services,” said BevCanna president Melise Panetta. “We are proud to be providing the firefighters with a special edition of our TRACE-branded natural 7.7ph alkaline spring water, sourced directly from our proprietary BC interior aquifer — the very land and forest that they work so hard to keep safe.” The government supply agreement calls for a limited-edition run of bottled water from BevCanna’s own alkaline spring water source, where the natural, slow filtration of pristine backcountry rain and melted snow through layers of rock and stone create a clean taste experience. The company’s TRACE-branded, mineralized water contains essential trace minerals that help combat illness and disease associated with trace mineral deficiency (https://ibn.fm/O4j57). The special-run bottles are manufactured in the company’s world-class, 40,000-square-foot, HACCP-certified manufacturing facility, which can produce up to 210 million bottles a year. In addition, these memorable water bottles bear a unique label with a personalized message to BC Wildfire Service personnel: Thanks For Being Our BadA** Hero. “We’ve already begun production and delivery to the firefighters,” said Panetta, who noted that the B.C. Ministry of Forests, Lands, Natural Resource Operations and Rural Development is responsible for the stewardship of provincial Crown land and ensures the sustainable management of forest, wildlife, water and other land-based resources. “We think that it’s very fitting that these heroes will be kept hydrated with BC’s own TRACE-branded water,” she said. In addition, the company’s scalable and flexible manufacturing process provides white-label solutions for third-party companies looking to enter this promising space with the highest-quality products available. A manufacturer of traditional and cannabis-infused beverage brands, the company is serving a growing roster of white-label clients. For more information on BevCanna, visit the company’s website at www.BevCanna.com. NOTE TO INVESTORS: The latest news and updates relating to BVNNF are available in the company’s newsroom at http://ibn.fm/BVNNF

• Avricore Health has announced that it is ready to roll out its HealthTab rapid disease testing system in pharmacies across Canada
• The rapid disease testing system comprises two key components, Avricore’s web-based HealthTab and Abbott’s Affinion 2 multi-assay analyzer
• The global point-of-care diagnostics market was valued at $34.49 billion in 2020 and is expected to continue growing and reach $81.37 billion by 2028

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF), an innovator in pharmacy services focused on the acquisition and development of early-stage technology aimed to move pharmacies forward, is set to roll out its proprietary HealthTab rapid disease testing system in pharmacies across Canada. The rollout comes shortly after the company put its health screening system into 12 Shoppers Drug Mart stores located in the Greater Toronto area, as well as several independent pharmacies in Ontario and British Columbia (https://ibn.fm/B70bn). “This adds a new dimension to the pharmacy practice. By providing this kind of service in a community pharmacy setting, we lower barriers to access to diagnostic information that’s often life-saving and outcome-improving,” Hector Bremner, CEO of Avricore, said. “Ultimately, we’re democratizing access to diagnosis while addressing the needs of pharmacists as they look to getting into more clinical services.” Avricore’s screening process is built upon two key components — HealthTab and Affinion 2. HealthTab is Avricore’s web-based platform. It provides a console-accessible interface where patients can create an account and choose their tests, allowing pharmacists to review and monitor patient information. The Affinion 2 multi-assay analyzer, created by Abbott Laboratories, provides point-of-care patient testing. Once the patient has registered and chosen a test, a pharmacist extracts a small amount of blood through a finger stick. The blood is then collected into a reagent disc and inserted into the Affinion 2. The results are ready in approximately 15 minutes. They are presented in a dashboard format that can be viewed from a computer, mobile device, or printed at the pharmacy. The information integrates easily into pharmacy EMR systems. The screening system can measure up to 21 health markers and currently offers diabetes and cardiovascular disease testing. Depending on the factors, analyzer and number of testing instruments, pharmacies pay between $300 and $500 a month for the system plus the per-test cost between $15 to $40 to cover the single-use test cartridges. Recently, Bremner sat down and spoke with Paul Benwell & Associates (“PBA”) for the “PBA à Noon” podcast, discussing HealthTab and the rapid diagnostic testing services (https://ibn.fm/lRecb). He highlighted the uniqueness of the company’s overall business structure — taking existing technology, bundling it together, and re-introducing it as an innovative service that people want and need. Through HealthTab, data connections are created to interlock the pharmacies, patients and medical doctors. The ecosystem is created to provide seamless patient care while sharing information with telemedicine or other medical professionals for research for expedited real-time reporting capability. The system can be adapted to provide real-time infectious disease tracking. Avricore’s goals for its rapid testing include expansion into more pharmacies across Canada and entry into the United States and United Kingdom’s markets. The partnerships that Avricore has created with companies like Abbott and the select Shoppers Drug Mart pharmacies place Avricore in a prime position to dominate the point-of-care (“POC”) diagnostics landscape — an expanding market rife with opportunities. According to a Fortune Business Insights report, the global POC diagnostics market was valued at $34.49 billion in 2020 and an estimated $43.49 billion in 2021 (https://ibn.fm/wWQSV). The market is expected to continue expanding and reach $81.37 billion in 2028, growing at a CAGR of 9.4% during the forecast period. For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• Flora Growth Corp recently received coverage from Argus Research, which gives the company’s stock a fair value estimate of $7.50 against the $3.24 recorded July 20
• Argus also projects that Flora’s revenue would increase to $9 million in 2021 and $31 million in 2022, up from $0.1 million reported in 2020
• Flora received a boost in its operations when Colombia’s president accepted and signed reforms to the existing cannabis legislation
• The updated law allows for the manufacture, sale and export of psychoactive (high-THC) cannabinoid ingestible and medical products and removes marketing limitations on cannabis products in Colombia
• Flora is also planning to relocate its headquarters to Miami by Q1 2022

Founded in 2019 and leveraging low-cost cannabis cultivation, an expansive brand and product portfolio, and a strategic global distribution platform, Flora Growth Corp. (NASDAQ: FLGC), an internationally focused cannabis consumer packaged goods company, was featured in a recently released equity research report by Argus Research Company (https://ibn.fm/5mNd1). Argus believes Flora is attractively valued relative to its peers based on its low-cost structure, robust brand portfolio and growing worldwide distribution. It further offers its stock a fair value estimate of $7.50 per share, more than 100% above the $3.24 recorded on July 20. The valuation, calculated using the EV/revenue analysis based on the Argus’ projection of Flora’s 2022 revenue of $32 million — up from a reported 0.1 million in 2020 and an estimated $9 million in 2021 — and an assumption that the company will have $30 million in cash, indicates that FLGC is seen as a worthy stock to follow and perhaps invest in. In its earnings and growth analysis, Argus notes that its revenue forecasts for both 2021 and 2022 exclude the impact of recently announced transactions, suggesting that FLGC’s share price could exceed the $7.50 per share fair value estimate. The transactions Argus was alluding to are a signed letter of intent (“LOI”) to acquire 100% of Koch & Gsell, a leading natural Swiss hemp product manufacturer and owner of hemp brand Heimat, for a stock-based consideration of about $22.2 million, and another LOI for an initial equity investment of approximately $2.4 million (€2 million) into Hoshi International, a vertically integrated medical cannabis company. Kock & Gsell boasts a retail network of more than 2,500 stores in Switzerland and can produce more than 40,000 packs of hemp and hemp-tobacco-blended cigarettes per day. Flora views this acquisition as an opportunity to enter the Swiss market and to leverage their proprietary technology by bringing it to other international markets, while Argus believes this transaction will potentially expand FLGC’s revenue. The equity investment in Hoshi aims to strengthen Flora’s European supply chain and offer access to the rapidly growing EU market. Hoshi, which has a finished products facility in Malta and a wholesale processing facility in Portugal, already has distribution agreements in Poland and Germany, while in other European countries the negotiations are still ongoing. “The investment will establish Flora as a preferred strategic supplier for Hoshi and provide it with a European manufacturing presence and the ability to import Colombian-grown flower and derivatives into Europe,” reads the report (https://ibn.fm/oaMml). Notably, the equity investment comes as the Colombian government, through the president, accepted and signed into effect reformed cannabis legislation aimed at augmenting access to cannabis products for Colombians. The revision also allows for the manufacture, sale and export of psychoactive (high-THC) cannabinoid ingestible products, removes marketing limitations on cannabis products in Colombia, and legalizes the sale of CBD medical products (https://ibn.fm/q44v1). For Flora’s Kasa Wholefoods, a company that produces food and beverages, the change is welcome news. With a distribution agreement to supply food products to Tropi, Colombia’s largest food distributor boasting a distribution network of more than 130,000 points across 38 cities, already announced, the legislative update is expected to increase revenue growth and generate even greater sales of its hemp and CBD products than initially anticipated. Moreover, the change bodes well for Flora Lab, FLGC’s derivative manufacturing and R&D center. The revised law also positions Colombia as the leader to supply the international cannabis market, leveraging its favorable climate for cannabis cultivation and its low production cost in certain regions of the country. Flora immediately reacted to the legislative update by signing an LOI with Kiricann, a South Africa-based international distributor with distribution agreements in the EU and Germany, to supply raw cannabis materials (dried flower) and its derivatives. Flora expects to sign more of these agreements in the near future as the global cannabis market starts taking note of Colombia’s high-quality cannabis and low-cost production. Located near the equator, Flora’s Cosechemos cultivation facility enjoys 12.8 hours of daily sunlight throughout the year, translating to an average daily temperature of 65°F. Additionally, the Bucaramanga region experiences consistent three mph wind that reduces instances of harmful, wind-borne pathogens and pollens. Additionally, the region’s organic nutrient-rich soil permits high-density planting and is some of the most fertile soil in the world. Flora also has access to highly skilled and affordable labor at only 10% of the cost of hiring such a workforce in the United States. Flora’s cultivation property combines all these advantages with additional benefits exclusive to its expansive farm — Cosechemos is licensed to grow cannabis on 247 acres. These unique benefits include the presence of six natural spring water deposits within the sizeable facility, as well as a $10/acre long-term monthly lease. The overall result is the ability to cultivate both high-THC and high-CBD cannabis at a production cost of $0.06 per gram, which is 60% lower than its closest Colombian competitor’s reported cost of $0.15. In comparison, North America-based cannabis producers average a production cost of $1.89 per gram (https://ibn.fm/F0Ri). Elsewhere, Flora also announced its plans to relocate its headquarters to Miami, specifically in Florida’s Brickell financial district, by Q1 2022 (https://ibn.fm/ZnjnE). This announcement follows an exhaustive review process guided by the company’s focus on creating global growth opportunities. According to Flora Growth President and CEO Luis Merchan, Miami satisfied the following requirements: travel & logistics (including time zone), business climate (state corporate tax rate and receptiveness to the cannabis industry), and personal life factors (including talent pool and cost-of leaving). For more information, visit the company’s website at www.FloraGrowth.ca. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• InMed announced a non-binding letter of intent to acquire BayMedica Inc.
• The move is designed to grow InMed’s market presence and strengthen its operations
• The two companies have had a reciprocal research collaboration that dates back to November 2020
• InMed looks to capitalize on the growing cannabinoid industry that is projected to grow at a CAGR of 21.2% from 2021 to 2028

InMed Pharmaceuticals (NASDAQ: INM) is a clinical-stage company committed to developing cannabinoid-based pharmaceutical drug candidates. It also manufactures technologies for pharmaceutical-grade rare cannabinoids. It is known for creating a pipeline of cannabinoid-based pharmaceutical drug candidates to treat various diseases with high unmet medical needs. In a move to grow its market presence and strengthen its operations, the company announced that it had entered into a non-binding letter of intent (“LOI”) to acquire BayMedica Inc. (https://ibn.fm/WJSW5). This announcement followed the two parties’ reciprocal Research Collaboration Agreement back in November 2020, which saw them collaborate on several projects since (https://ibn.fm/WJSW5). The agreement allowed BayMedica to assess particular elements of InMed’s proprietary IntegraSyn(TM) approach in producing cannabinoids. In addition, InMed began a preclinical investigation of different compounds selected from BayMedica’s extensive library of proprietary cannabinoid analogs, designed to be developed to treat human diseases. While making the announcement, Eric A. Adams, the president and chief executive officer (“CEO”) of InMed, noted: “We are very excited about the prospect of continuing to work with BayMedica and the potential to build a leading rare cannabinoid company together (https://ibn.fm/WJSW5).” He further noted that: “Since commencing our collaboration in November last year, it has become apparent that our complementary business models and capabilities have the potential to provide a platform to expedite the growth of both companies and provide the flexibility of multiple processes for the manufacturing of rare cannabinoids.” The acquisition is intended to turn InMed into a powerful cannabinoid manufacturing company. With the company’s IntegraSyn(TM) pharmaceutical-grade manufacturing process, along with BayMedica’s rare cannabinoid manufacturing and ongoing revenue generation, Mr. Adams reckons that the company’s overall value proposition to customers would increase significantly, all while allowing the company to position itself at the forefront of the growing rare cannabinoid sector (https://ibn.fm/T8sD8). BayMedica is a biotechnology company that utilizes its expertise in synthetic biology and pharmaceutical chemistry to develop scalable, efficient and proprietary manufacturing approaches (https://ibn.fm/2068U). With this, it is known to produce regulatory-compliant, high-quality rare cannabinoids designed for the consumer market. Currently, BayMedica is commercializing the rare cannabinoid cannabichromene (“CBC”) as a business-to-business (“B2B”) supplier to distributors and manufacturers who are providing it in the health and wellness sector. The company is targeting additional rare cannabinoid launches for 2022. InMed is committed to becoming a leader in the cannabinoid sector. This move to acquire BayMedica confirms its ambition, along with the successful collaboration that the two companies have had so far. For more information, visit the company’s website at www.InMedPharma.com. NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

• Brain Scientific poised to disrupt neurology market with two new FDA-cleared patented products that provide cost-effective brain imaging in any setting
• Current global market for EEG devices estimated at $956.1 million with CAGR of 8.7% from 2019 to 2026, expected to reach $1.6 billion by 2026

With a focus on developing innovative and proprietary medical devices and software, Brain Scientific (OTCQB: BRSF), a commercial-stage health care company, is fulfilling its mission of modernizing and increasing accessibility to brain diagnostics with two new FDA-cleared products that provide next-generation solutions to the neurology market. Already patented in the United States, China and Europe, the company’s first commercialized devices — the NeuroCap(TM) and NeuroEEG(TM) — are designed to disrupt the current electroencephalogram (“EEG”) market by offering a cost-effective and disposable alternative to existing solutions. The NeuroCap is a disposable pre-gelled EEG headset that features 22 electrodes and 19 active EEG channels that all adhere to the international 10-20 system. Cleared by the FDA in 2018, the headset can be used for recording EEGs in nearly any setting, including neurology clinics, remote clinical research labs, emergency departments, urgent care clinics, ICUs, nursing homes and assisted living facilities. Intended for prescription use, the NeuroEEG is a compact, portable and cost-effective FDA-cleared, clinical-grade wireless EEG amplifier that acquires, records, displays and transmits electrical brain activity for patients of all ages. Both the NeuroEEG and NeuroCap are delivered by MemoryMD Inc., the predecessor and now wholly owned subsidiary of Brain Scientific. Brain Scientific’s development process spans three stages. The first development phase, from 2018 to 2019, resulted in the inception of the company’s portable, clinical-grade, easy-to-use neurological devices. The second, ongoing phase currently focuses on the creation of cloud-based, secure infrastructure to transmit patient data between patients and neurologists. The final and third phase — scheduled for 2021-2023 — aims to focus on the use of AI to facilitate diagnostic analysis and increase the consistency, efficiency, consistency and accuracy of imaging by neurology specialists. Brain Scientific plans on expanding the vision for telemedicine in neurology with an aim to address the current acute neurologist shortfall throughout the U.S. The current global market for EEG devices is estimated at $956.1 million with an expected CAGR of 8.7% from 2019 to 2026 and is expected to reach $1.6 billion by 2026 (https://ibn.fm/Ys8Qi). With its current marketing strategy and development pipelines, BRSF’s management projects significant market penetration in addition to opportunities to collaborate with other businesses — such as EEG manufacturers — that could package Brain Scientific’s solutions with their products and effectively expand the company’s addressable target market. Headquartered in New York, Brain Scientific and its wholly owned subsidiary MemoryMD Inc. were founded in 2015 and went public in 2018. With a focus on developing innovative medical devices and software that disrupt the brain diagnostics market, Brain Scientific is poised to take center stage with solutions that enable medical professionals to cost-effectively diagnose patients with consistency, efficiency and accuracy in virtually any setting. For more information on Brain Scientific Inc., visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF